What Affinity Biomarker Labs does

Affinity Biomarker Labs, trading as Affinity Laboratories Limited (UK Companies House number 10566588), is a London-based specialty biomarker testing laboratory founded in 2017 at Imperial College London's White City Campus by a team of clinical biochemists and analytical scientists. The company provides translational biomarker services spanning routine and esoteric biomarker analysis, assay validation and tech transfer, companion diagnostic assay development, biobanking, and analytical consultancy. Service delivery is supported by approximately 2,500 validated biomarker tests run across seven analytical platforms, including ELISA, clinical chemistry analysers, Mesoscale Discovery and Randox multiplex immunoassays, Siemens Centaur, Evidence Investigator biochip arrays, Siemens Advia 560 haematology, and mass spectrometry, with sample matrices including serum, plasma, urine, saliva, faeces, and CSF.

The company operates a direct, professional services engagement model targeting three primary verticals: academic research institutions, biopharmaceutical companies, and clinical healthcare settings. GTM is anchored by enterprise field sales combined with professional services consultancy, with project initiation via website inquiry, email ([email protected]), or phone (0208 090 1307). Pricing is quote-based and customized per project, with services scaling from single-analyte discovery work to large longitudinal and multi-center clinical trial sample analysis. Named institutional partners include King's College Hospital, Imperial College London, Guy's and St Thomas' NHS Foundation Trust, and Newcastle University, indicating embedded relationships within UK academic and NHS research networks.

Operationally, the company is privately held and founder-owned, with Laboratory Director Tracy Neal leading scientific delivery and Andrew Given serving as Data Protection Officer. The business expanded into additional nearby laboratory facilities in January 2021 and currently lists a headcount band of 11-50 employees. No external funding rounds, acquisitions, patents, formal certifications, or public ratings have been disclosed in the source material.

Name

Affinity Biomarker Labs

Legal name

Affinity Laboratories Limited

Website

https://affinitybiomarkerlabs.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Affinity Biomarker Labs is a London-based specialty biomarker testing laboratory providing translational biomarker analysis, assay validation, companion diagnostic development, and biobanking services to academic researchers, biopharma companies, and clinical healthcare organizations across multiple analytical platforms.

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD)

Keywords

• Biomarker testing services
• Clinical biochemist laboratory
• Immunoassay analysis
• Companion diagnostics development
• Biobanking services

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Supply Chain, Operations

Revenue model

1. Biomarker Testing Services: Laboratory testing services for biomarker analysis ranging from routine tests to highly esoteric biomarker analysis. Services scale from small discovery cohorts through to large longitudinal studies and multi-center clinical trials. Pricing is quote-based as projects are customized to client requirements.
2. Assay Development and Validation: Assay validation, method optimization, and tech transfer services for biomarkers being transferred to Affinity's platforms. Includes diagnostic and companion assay development support.
3. Biobanking Services: Sample storage and biobanking services with cost-effective long-term storage options.
4. Analytical Consultancy: Diagnostic development services and analytical consultancy for biomarker projects and companion diagnostics development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Affinity Biomarker Labs is a UK-based biomarker testing laboratory that provides translational biomarker analysis services spanning routine to esoteric biomarker testing. The lab supports biomarker discovery, verification, validation, and analysis for academic research institutions, biopharmaceutical companies, and clinical healthcare organizations, using seven distinct analytical platforms covering approximately 2500 biomarkers across clinical chemistry, immunology, oncology, and specialty disease areas.

Product overview

Affinity Biomarker Labs is a biomarker testing laboratory offering a comprehensive portfolio of services centered on Translational Biomarker Services. The core offering includes Routine and Esoteric Biomarker Analysis with assay validation and testing capabilities, supported by a network of seven distinct testing platforms: ELISA, Clinical Chemistry Analyser, Mesoscale Discovery Multiplex Immunoassay, Randox Multiplex Immunoassay, Siemens Centaur, Evidence Investigator, and Siemens Advia 560 Haematology. The Test Menu encompasses approximately 2500 biomarker and diagnostic tests. Additional services include Companion Diagnostic Assay Development, Biobanking Services, Analytical Consultancy, and Method Tech Transfer Services. These services are delivered across three market segments: Biopharma (drug development and companion diagnostics), Academia (fundamental research), and Clinical (biomarker-guided clinical decision making).

Differentiator

Problem solved

Functional benefit

Products and services

• Routine and Esoteric Biomarker Analysis Biomarker testing services ranging from routine tests to highly esoteric biomarker analysis, supporting study sizes from single analytes to multiplex assay panels across serum, plasma, urine, saliva, faeces, and CSF. Targets academic and biopharma research clients.
• Assay Validation and Testing Single analyte and multiplex assay validation and testing services including preanalytical factors assessment, sample collection assessment, and sample and analyte stability testing. Serves biopharma and academic clients transferring assays.
• Companion Diagnostic Assay Development Support for diagnostic and companion assay development including platform validation and clinical sample analysis for biopharma drug co-development programs.
• Biobanking Services Cost-effective, long-term sample storage services for research and clinical trial specimens, supporting clients' biobanking needs.
• Analytical Consultancy Diagnostic development services providing analytical expertise and consultancy for biomarker projects and companion diagnostics development.
• Method Tech Transfer Services Method optimisation and validation for assays transferred to Affinity Biomarker Labs, including assay validation and testing workflows.
• Biopharma Biomarker Services Biomarker analysis services supporting biopharma drug development, companion diagnostics co-development, and clinical trials from discovery cohorts through multi-center studies.
• Academic Research Biomarker Services Biomarker analysis services supporting academic research groups with assay validation and application for fundamental scientific research projects.
• Clinical Biomarker Development Services Clinical biomarker development services supporting preventative, diagnostic, prognostic, predictive, and therapeutic biomarker applications in clinical settings.

Quantifiable outcome

• Fast turnaround times for complex biomarker projects
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered founding and core.

• Imperial College LondonfoundingStrategic or Co-development PartnerAffinity Biomarker Labs was originally established in 2017 at Imperial College London White City Campus. The company maintains close working relationships with academic institutions for research collaboration and talent acquisition.
• King's College HospitalcoreStrategic or Co-development PartnerLaboratory Director Tracy Neal previously founded and managed the R&D laboratory within King's College Hospital Department of Biochemistry. The company maintains close working relationships with teaching hospitals for clinical biomarker development programs.
• Guy's and St Thomas' NHS Foundation TrustcoreStrategic or Co-development PartnerClose working relationship with leading teaching hospital for clinical biomarker development programs and research collaboration.
• Newcastle UniversitycoreStrategic or Co-development PartnerAcademic partner for clinical biomarker development programs and research collaboration in the North of England.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Celerion: Specialised early-phase clinical research and bioanalytical services organisation with biomarker assay capabilities. Comparable to Affinity because both serve biopharma with specialty biomarker analysis and assay validation; Celerion is a closer-size direct peer in the niche CRO space.
• BioAgilytix Labs: Specialised bioanalytical and biomarker testing CRO focused on large-molecule biopharma, with platforms including MSD multiplex immunoassays. Highly comparable to Affinity as a specialty biomarker lab serving biopharma with multiplex and immunoassay capabilities; operates at slightly larger scale.

Broad incumbents

• Pharmaron: Integrated CRO with bioanalytical and biomarker services across discovery through clinical development. Comparable to Affinity in offering biomarker assay development, validation, and clinical sample analysis for biopharma, but operates globally at significantly greater scale.
• Eurofins Scientific: Global life sciences testing group with extensive biomarker, immunoassay, and central laboratory capabilities. Comparable to Affinity because both operate specialty biomarker testing services for biopharma and academic clients, but Eurofins is a broad incumbent with far greater scale, geographic footprint, and accreditations.
• Bio-Techne: Life science tools and services company with biomarker assay products, GMP analytical services, and multiplex platforms (including partnerships with Meso Scale Diagnostics-adjacent technologies). Comparable to Affinity in offering validated biomarker assays and analytical services, but Bio-Techne is a broad incumbent with proprietary reagent and kit portfolio.
• ICON plc: Global CRO with central laboratory services and biomarker assay capabilities supporting clinical trials. Comparable to Affinity in providing specialty biomarker testing for biopharma clinical programmes, but ICON is a broad incumbent with global capacity, accreditations, and a Phase I–IV trial sponsor base.
• Charles River Laboratories: Large CRO with biomarker and bioanalytical services supporting drug development. Comparable to Affinity in the biomarker assay and validation workflow it offers to biopharma, but Charles River is a broad incumbent with global reach and integrated safety/efficacy services.
• Myriad Genetics (including RBM biomarker services): Diagnostics and biomarker services company, including multi-analyte profiling services for clinical research and biopharma. Comparable to Affinity in providing specialty multiplex biomarker assays and analytical services, but Myriad is a broader, publicly-listed incumbent with established companion diagnostic franchises.
• SGS (Life Sciences): Global testing and CRO group with clinical and bioanalytical laboratory services including biomarker assays. Comparable to Affinity in providing biomarker testing services for biopharma and academic clients, but SGS is a broad incumbent with international footprint and accreditations Affinity lacks.
• Labcorp (including its central lab and early development services): Major CRO and central laboratory offering biomarker assay development, validation, and clinical trial sample analysis. Comparable because both run specialty biomarker assays in support of clinical trials and biopharma programmes; Labcorp is a broad incumbent with global capacity Affinity does not have.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/share.php?u=https://affinitybiomarkerlabs.com
• Xtwitter.com/share?url=https://affinitybiomarkerlabs.com

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Affinity Biomarker Labs